Interleukin-22, a potent target for treatment of non-autoimmune diseases

Hum Vaccin Immunother. 2018;14(12):2811-2819. doi: 10.1080/21645515.2018.1509649. Epub 2018 Oct 31.

Abstract

Interleukin -22 (IL-22) is a member of interleukin-10 (IL-10) family cytokines that is produced by different types of lymphocytes included in both innate and adaptive immune systems. These lymphocytes include activated T cells, most notably Th17 and Th22 cells, as well as NK cells, γδ T cells, etc. IL-22 mediate its effects via the IL-22-IL-22R complex and subsequent Janus Kinase-signal transduces and activators transcription (JAK-STAT) signaling pathway. According to recent evidence, IL-22 played a critical role in the pathogenesis of many non-autoimmune diseases. In this review, we mainly discussed the recent findings and advancements of the role of IL-22 in several non-autoimmune diseases, such as acute lung injury, atherosclerosis and some bacterial infections, suggesting that IL-22 may have therapeutic potential for treating non-autoimmune diseases.

Keywords: Interleukin-22; disease treatment; interleukin-10; non-autoimmune diseases.

Grants and funding

No.